<DOC>
	<DOCNO>NCT02661542</DOCNO>
	<brief_summary>A Phase 1/2a , dose-escalation study FF-10502-01 Patients Advanced Solid Tumors Lymphomas . A total 9 cohort enrol Phase 1 establish MTD . Phase 2 consist 2 cohort : Cohort 1 include subject Pancreatic Cancer . Cohort 2 include subject another tumor type enrol Phase 1 dose-escalation phase demonstrate Clinical Benefit Week 16 .</brief_summary>
	<brief_title>Study FF-10502-01 Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>Subjects receive dose FF-10502-01 intravenously ( IV ) weekly three week , repeat every 28 day ( = 1 cycle ) . Disease assessment , base compute tomography ( CT ) , magnetic resonance image ( MRI ) , , lymphoma , [ 18F ] -fluorodeoxyglucose positron emission tomography ( FDG-PET ) scan , obtain Week 8 every 8 week thereafter document progression disease ( PD ) . Subjects demonstrate clinical benefit allow continue therapy FF-10502-01 progression disease , observation unacceptable adverse event , intercurrent illness change subject 's condition prevents study participation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Males female ≥ 18 year age Histologically cytologically confirm advanced metastatic solid tumor l lymphoma , refractory standard therapy , relapse standard therapy , standard therapy available expect improve survival least three month At least 4 week beyond last chemotherapy ( ≥ 5 halflives target agent , whichever short ) , radiotherapy , major surgery experimental treatment recover acute toxicity ( ≤ Grade 1 ) Adequate performance status : Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 Life expectancy ≥ 3 month Adequate hematologic parameter without ongoing transfusional support : Hemoglobin ( Hb ) ≥ 9 g/dL Absolute neutrophil count ( ANC ) ≥ 1.0 x 109 cells/L Platelets ≥ 100 x 109 cells/L Adequate renal hepatic function : Creatinine ≤ 1.5 x upper limit normal ( ULN ) , calculate creatinine clearance ≥ 60 mL/minute x 1.73 m2 per CockcroftGault formula Total bilirubin ≤ 2 time upper limit normal ( ULN ) unless due Gilbert 's disease ALT/AST ≤ 2.5 time ULN , &lt; 5 time ULN subject liver metastasis QT interval correct rate ( QTc ) ≤ 480 msec electrocardiogram ( ECG ) obtain Screening Negative serum pregnancy test within 14 day prior first dose study therapy woman childbearing potential ( WCBP ) , define sexually mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . Sexually active WCBP male subject must agree use adequate method avoid pregnancy ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) throughout study 28 day completion study treatment . Ability provide write informed consent Serious cardiac condition within last 6 month , uncontrolled arrhythmia , myocardial infarction , unstable angina heart disease define New York Heart Association ( NYHA ) Class III Class IV Concomitant medication ( ) may cause QTc prolongation induce Torsades de Pointes , exception antimicrobial use standard care prevent treat infection drug consider Investigator essential patient care Active central nervous system ( CNS ) malignant disease subject history CNS malignancy . Subjects stable , prior currently treat brain metastasis allow . Known positive human immunodeficiency virus ( HIV ) , hepatitis B virus surface antigen ( HBsAg ) hepatitis C virus ( HCV ) Active infection require intravenous ( IV ) antibiotic usage within last week prior study treatment Any medical intervention condition , opinion Principal Investigator , could compromise adherence study requirement confound interpretation study result Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>